期刊文献+

新型E-2,3-二芳基丙烯酰氧基膦酸酯衍生物的设计、合成与抗肿瘤活性 被引量:4

Design, synthesis and antitumor activities of novel E-substituted 2, 3-diaryl propenoic acyloxy phosphonate derivatives
原文传递
导出
摘要 根据活性片段组合原理,设计、合成了一系列新型E-2,3-二芳基丙烯酰氧基膦酸酯衍生物,结构经IR、1H NMR、13C NMR及元素分析确证。采用MTT法测试目标化合物的抗肿瘤活性。结果表明:部分化合物对于所测试肿瘤细胞有抑制作用,其中化合物3e对A-549的活性[IC50=(12.7±1.9)μmol·L-1]最为突出,与对照药顺铂[IC50=(8.0±1.5)μmol·L-1]较为接近;化合物3g、3k对EC-109的增殖抑制作用最好,IC50分别为(9.5±1.8)μmol·L-1和(11.5±0.9)μmol·L-1;化合物3i、3k对SGC-7901、A-549、EC-109三种肿瘤细胞均有较好抑制作用。该类衍生物值得进一步研究。 According to the super-position principle of the reinforcement of biological activities, a series of novel E-substituted 2, 3-diaryl propenoic acyloxy phosphonate derivatives were designed and synthesized. And the structures of the target compounds were confirmed by IR, 1H NMR, 13 C NMR and elemental analysis. Furthermore, the cytotoxicities of all compounds on A-549, SGC-7901 and EC-109 in vitro were evaluated by MTT assay, and some of them showed good antitumor activity. Among the active compounds, especially, the IC50 value of compound 3e was(12.7 ± 1.9) μmol·L-1 against A-549 cells, similar to cisplatin [IC50 =(8.0 ± 1.5) μmol·L-1], compounds 3g and 3k had better inhibition effect on EC-109 cells growth, with the IC50 values of(9.5 ± 1.8) μmol·L-1 and(11.5 ± 0.9) μmol·L-1 respectively, and compounds 3i and 3k exhibited good cytotoxic property on A-549, SGC-7901 and EC-109, which were worth further investigation.
出处 《药学学报》 CAS CSCD 北大核心 2015年第4期464-468,共5页 Acta Pharmaceutica Sinica
基金 贵州省科技厅国际合作基金资助项目(黔科合外G字[2014]7013) 贵州省教育厅黔科合人才团队项目([2012]03)
关键词 丙烯酸 膦酸酯 合成 抗肿瘤活性 propenoic acid phosphonate synthesis antitumor activity
  • 相关文献

参考文献6

二级参考文献66

  • 1陈冬梅,陈凯,汪海.吗啉环和哌嗪环类衍生物的抗血栓作用及其分子机制[J].药学学报,2003,38(9):641-645. 被引量:10
  • 2刘新华.新型芳基吡唑衍生物的合成及其抑菌活性[J].合成化学,2007,15(2):212-215. 被引量:4
  • 3Yuen MF, Lai CL. Adefovir dipivoxil in chronic hepatitis B infection [ J ]. Expert Opin Pharmacother, 2004,5 : 2361 - 2367.
  • 4Hwang JT, Choi JR. Novel phosphonate nucleoside as antiviral agents [ J]. Drugs Future, 2004,29 : 163 - 177.
  • 5Sweet DH, Bush KT, Nigam SK. The organic anion transporter family: from physiology to ontogeny and the clinic [ J]. Am J Physiol Renal Physiol, 2001,281:F197 - F205.
  • 6Benzaria S, Pelicano H, Johnson R, et al. Synthesis, in vitro antiviral evaluation, and stability studies of bis (Saeyl-2-thioethyl) ester derivatives of 9-[ 2-( phosphono- methoxy) ethyl] adenine (PMEA) as potential PMEA prodrugs with improved oral bioavailability [ J ]. J Med Chem, 1996,39:4958 -4965.
  • 7Meris C, Gorbig U, Muller C, et al. CycloSal-PMEA and cycloAmb-PMEA: potentially new phosphonate prodrugs based on the cycloSal-pronucleotide approach [ J ]. J Med Chem, 2005,48:8079 - 8086.
  • 8Erion MD, Reddy KR, Boyer S, et al. Design, synthesis, and characterization of a series of cytochrome P (450) 3A-activated prodrugs ( HepDirect prodrugs ) useful for targeting phosph (on)ate-based drugs to the liver [J]. J Am Chem Soc, 2004,126:5154 -5163.
  • 9Carsten UN, Birger B, Flemming SJ, et al. Human peptide transporters : therapeutic applications [ J ]. Expert Opin Ther Patents, 2002,12 : 1329 - 1350.
  • 10Isabel RA, Hannelore D. Mammalian peptide transporters as targets for drug delivery [ J ]. Trends Pharmacol Sci, 2003,23:434 - 440.

共引文献32

同被引文献14

引证文献4

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部